Decoy Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Decoy Therapeutics Inc. (DCOY) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.93% as of 2021-09-02, per its 10-Q filed 2021-11-04.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2022-05-12
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 0.48%.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 1.61%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2021-09-02 | 0.93% 10-Q · filed 2021-11-04 | |||
| 2021-06-16 | 1.09% 10-Q · filed 2021-11-04 | |||
| 2021-03-10 | 1.00% 10-Q · filed 2022-05-12 | |||
| 2020-09-16 | 0.38% 10-Q · filed 2020-11-12 | |||
| 2020-07-14 | 0.37% 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 0.48% 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | 0.48% 10-Q/A · filed 2020-05-15 | |||
| 2020-03-23 | 0.48% 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 1.61% 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |